99 related articles for article (PubMed ID: 1918387)
1. Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis.
Limaye AP; Abrams JS; Silver JE; Awadzi K; Francis HF; Ottesen EA; Nutman TB
J Clin Invest; 1991 Oct; 88(4):1418-21. PubMed ID: 1918387
[TBL] [Abstract][Full Text] [Related]
2. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
3. Eosinophil degranulation. An immunologic determinant in the pathogenesis of the Mazzotti reaction in human onchocerciasis.
Ackerman SJ; Kephart GM; Francis H; Awadzi K; Gleich GJ; Ottesen EA
J Immunol; 1990 May; 144(10):3961-9. PubMed ID: 2332637
[TBL] [Abstract][Full Text] [Related]
4. Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis.
Hagan JB; Bartemes KR; Kita H; Ottesen EA; Awadzi K; Nutman TB; Gleich GJ
J Infect Dis; 1996 May; 173(5):1277-80. PubMed ID: 8627086
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.
Limaye AP; Ottesen EA; Kumaraswami V; Abrams JS; Regunathan J; Vijayasekaran V; Jayaraman K; Nutman TB
J Infect Dis; 1993 Jun; 167(6):1396-400. PubMed ID: 8501330
[TBL] [Abstract][Full Text] [Related]
6. Extraordinarily high eosinophilia and elevated serum interleukin-5 level observed in a patient infected with Paragonimus westermani.
Kan H; Ogata T; Taniyama A; Migita M; Matsuda I; Nawa Y
Pediatrics; 1995 Aug; 96(2 Pt 1):351-4. PubMed ID: 7630699
[TBL] [Abstract][Full Text] [Related]
7. [Eosinophil colony stimulating factor (Eo-CSF) activity and soluble interleukin-2 receptor (sIL-2R) in patients with reactive eosinophilia].
Watanabe K; Enokihara H; Saito K; Furusawa S
Arerugi; 1995 Nov; 44(11):1317-21. PubMed ID: 8857112
[TBL] [Abstract][Full Text] [Related]
8. Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin.
Cooper PJ; Awadzi K; Ottesen EA; Remick D; Nutman TB
J Infect Dis; 1999 Mar; 179(3):738-42. PubMed ID: 9952390
[TBL] [Abstract][Full Text] [Related]
9. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice.
Mould AW; Matthaei KI; Young IG; Foster PS
J Clin Invest; 1997 Mar; 99(5):1064-71. PubMed ID: 9062365
[TBL] [Abstract][Full Text] [Related]
10. Association of transient dermal mastocytosis and elevated plasma tryptase levels with development of adverse reactions after treatment of onchocerciasis with ivermectin.
Cooper PJ; Schwartz LB; Irani AM; Awadzi K; Guderian RH; Nutman TB
J Infect Dis; 2002 Nov; 186(9):1307-13. PubMed ID: 12402200
[TBL] [Abstract][Full Text] [Related]
11. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration.
Sosman JA; Bartemes K; Offord KP; Kita H; Fisher SG; Kefer C; Ellis TA; Fisher RI; Higgins TJ; Gleich GJ
Clin Cancer Res; 1995 Aug; 1(8):805-12. PubMed ID: 9816049
[TBL] [Abstract][Full Text] [Related]
12. Inhaled corticosteroid effects both eosinophilic and non-eosinophilic inflammation in asthmatic patients.
Basyigit I; Yildiz F; Ozkara SK; Boyaci H; Ilgazli A
Mediators Inflamm; 2004 Aug; 13(4):285-91. PubMed ID: 15545060
[TBL] [Abstract][Full Text] [Related]
13. [Dysregulation of cooperative interactions of immunocytes and eosinophils in the mechanism of development of eosinophilia in Opisthorhis felineus invasion].
Litvinova LS; Riazantseva NV; Novitskiĭ VV
Med Parazitol (Mosk); 2008; (3):13-7. PubMed ID: 18819423
[TBL] [Abstract][Full Text] [Related]
14. [Rapidly progressive, refractory eosinophilia with a 250,000/microliter eosinophil count].
Noguchi M; Okumura K; Kato A; Hirano T; Oshimi K
Rinsho Ketsueki; 2000 Feb; 41(2):135-9. PubMed ID: 10723243
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease.
Bhattacharya B; Carlsten J; Sabo E; Kethu S; Meitner P; Tavares R; Jakate S; Mangray S; Aswad B; Resnick MB
Hum Pathol; 2007 Dec; 38(12):1744-53. PubMed ID: 17900656
[TBL] [Abstract][Full Text] [Related]
16. The relationship of sputum eosinophilia and sputum cell generation of IL-5.
Liu LY; Swensen CA; Kelly EA; Kita H; Busse WW
J Allergy Clin Immunol; 2000 Dec; 106(6):1063-9. PubMed ID: 11112887
[TBL] [Abstract][Full Text] [Related]
17. Eosinophil differentiation factor (interleukin-5).
Sanderson CJ
Immunol Ser; 1990; 49():231-56. PubMed ID: 2090253
[TBL] [Abstract][Full Text] [Related]
18. Chemokines in onchocerciasis patients after a single dose of ivermectin.
Fendt J; Hamm DM; Banla M; Schulz-Key H; Wolf H; Helling-Giese G; Heuschkel C; Soboslay PT
Clin Exp Immunol; 2005 Nov; 142(2):318-26. PubMed ID: 16232219
[TBL] [Abstract][Full Text] [Related]
19. Eosinophils involved in fulminant hepatic failure are associated with high interleukin-6 expression and absence of interleukin-5 in liver and peripheral blood.
dos Santos DC; da Silva Gomes Martinho JM; Pacheco-Moreira LF; Carvalho Viana de Araújo C; Caroli-Bottino A; Pannain VL; Soares Trinta K; Gandini M; da Costa Neves PC; de Souza Matos DC; Gonçalves Caputo LF; Pelajo-Machado M; Alves Pinto M
Liver Int; 2009 Apr; 29(4):544-51. PubMed ID: 19323781
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilia in primary biliary cirrhosis.
Yamazaki K; Nakadate I; Suzuki K; Sato S; Masuda T
Am J Gastroenterol; 1996 Mar; 91(3):516-22. PubMed ID: 8633501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
